CHEMOMAB THERAPEUTICS LTD
CMMBNASDAQTrading Snapshot
- Day Range
- $1.60 – $1.63
- 52-Week Range
- $1.35 – $3.58
- Volume
- $3.57B
- Avg Volume
- $3.11B
- Shares Outstanding
- 6.2M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $468,166
- P/E Ratio
- -1.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.95
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +65.9%
Why Investors Own CMMB
- ✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CHEMOMAB THERAPEUTICS LTD
CMMB
StockOtter · stockotter.spaceAbout CHEMOMAB THERAPEUTICS LTD
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high u
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.